Delivering affordable, accurate point-of-care screening—transforming timely insights into improved risk stratification and better patient outcomes Liver disease (MASLD/MASH) and lung cancer are often fatal because they're detected late, when treatment options are limited. Most solutions are invasive, expensive, or underused, so about 83% of MASLD cases go undiagnosed and only 5% of those at risk for lung cancer are screened. Low trust, hesitant prescribers, and payer resistance cause further delays and misdirected care. We’ve developed a non-invasive AI-driven breath-sensing device detecting unique biomarker fingerprints with current application for screening for lung cancer and MASH advanced liver fibrosis screening, detecting unique biomarker fingerprints. With thousands of samples and clinical data collected from 10 sites, our tech shows 80% accuracy . higher accuracy than current existing tools. Sample collection takes 30 seconds and evaluation takes 5 minutes. Accessible and scalable, it addresses critical gaps in screening and risk stratification, where current solutions fall short. Backed by Horizon EU, EIC-Transition, the IIA, and Google, we’re rapidly advancing population health solutions. For Value-Based-Care Organizations: reduces unnecessary referrals (currently ~90%) delivers $3M cost saving per ACO on average and $10B in total for medicare. It streamlines workflows with a simple 2 min process and enhances both patient and user experience, leading to higher testing compliance. By enabling early detection and intervention, it reduces long-term costs of $20k–70k per patient. For Pharma: Unlocks underdiagnosed patient populations, builds real-world evidence to accelerate reimbursement and adoption, and increases physician trust by providing actionable results—optimizing trial stratification and ensuring therapies reach the right patients.